Caribou Biosciences, Inc. (CRBU) Operating Margin
- Operating margin · 12 months: Value -1090.90%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -1090.90% | Operating income / revenue. Period ending 2026-06-30. $-109.47M ÷ $10.04M × 100 ≈ -1090.90% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -109.47M USD | Operating Income (Loss) |
| Revenue | 10.04M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 85.77M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-109.47M | $10.04M | (m) | $85.77M | (m) | -1090.90% |
| 2026-03-31 | $-131.71M | $11.20M | (m) | $94.52M | (m) | -1175.68% |
| 2025-12-31 | $-148.34M | $11.16M | (m) | $109.44M | (m) | -1329.37% |
| 2025-09-30 | $-158.77M | $9.29M | (m) | $116.09M | (m) | -1708.08% |
| 2025-06-30 | $-167.60M | $9.12M | (m) | $124.11M | (m) | -1837.56% |
| 2025-03-31 | $-163.53M | $9.92M | (m) | $131.90M | (m) | -1648.79% |
| 2024-12-31 | $-166.62M | $9.99M | (m) | $130.15M | (m) | -1667.16% |
| 2024-09-30 | $-165.18M | $11.47M | (m) | $130.97M | (m) | -1439.50% |
| 2024-06-30 | $-141.58M | $33.11M | (m) | $129.13M | (m) | -427.56% |
| 2024-03-31 | $-130.94M | $33.40M | (m) | $120.15M | (m) | -392.00% |
| 2023-12-31 | $-116.06M | $34.48M | (m) | $112.08M | (m) | -336.63% |
| 2023-09-30 | $-109.19M | $34.61M | (m) | $106.53M | (m) | -315.49% |
| 2023-06-30 | $-121.10M | $14.25M | (m) | $97.94M | (m) | -849.70% |
| 2023-03-31 | $-116.66M | $14.69M | (m) | $94.02M | (m) | -794.21% |
| 2022-12-31 | $-106.40M | $13.85M | (m) | $82.23M | (m) | -768.17% |
| 2022-09-30 | $-96.23M | $12.72M | (m) | $71.61M | (m) | -756.61% |
| 2022-06-30 | $-88.31M | $13.39M | (m) | $67.45M | (m) | -659.39% |
| 2022-03-31 | $-74.66M | $10.68M | (m) | $56.01M | (m) | -699.30% |
| 2021-12-31 | $-66.98M | $9.60M | (m) | $52.26M | (m) | -697.84% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | $-38.87M | $12.25M | (m) | $35.95M | (m) | -317.41% |
| 2020-12-31 | $-36.12M | $12.36M | (m) | $34.42M | (m) | -292.24% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-34.30M | $5.79M | (m) | $23.64M | (m) | -592.69% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| LENZ Therapeutics, Inc. (LENZ) | United States | $0.117B | -1.41 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |